{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T16:13:10Z","timestamp":1785255190215,"version":"3.55.0"},"publisher-location":"Cham","reference-count":83,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783319228334","type":"print"},{"value":"9783319228341","type":"electronic"}],"license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015]]},"DOI":"10.1007\/978-3-319-22834-1_16","type":"book-chapter","created":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T12:47:40Z","timestamp":1443703660000},"page":"455-473","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The Development of Prophylactic and Therapeutic EBV Vaccines"],"prefix":"10.1007","author":[{"given":"Corey","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,10,2]]},"reference":[{"key":"16_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coviro.2014.02.005","volume":"6","author":"HH Balfour Jr","year":"2014","unstructured":"Balfour HH Jr (2014) Progress, prospects, and problems in Epstein-barr virus vaccine development. Curr Opin Virol 6:1\u20135","journal-title":"Curr Opin Virol"},{"issue":"9","key":"16_CR2","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/nrclinonc.2012.111","volume":"9","author":"CM Bollard","year":"2012","unstructured":"Bollard CM, Rooney CM, Heslop HE (2012) T-cell therapy in the treatment of post-transplant lymphoproliferative disease. Nat Rev Clin Oncol 9(9):510\u2013519","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"16_CR3","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/icb.2010.136","volume":"89","author":"SR Burrows","year":"2011","unstructured":"Burrows SR, Moss DJ, Khanna R (2011) Understanding human T-cell-mediated immunoregulation through herpesviruses. Immunol Cell Biol 89(3):352\u2013358","journal-title":"Immunol Cell Biol"},{"issue":"8","key":"16_CR4","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/nm0896-906","volume":"2","author":"MF Callan","year":"1996","unstructured":"Callan MF, Steven N, Krausa P et al (1996) Large clonal expansions of CD8+ T cells in acute infectious mononucleosis. Nat Med 2(8):906\u2013911","journal-title":"Nat Med"},{"key":"16_CR5","doi-asserted-by":"crossref","unstructured":"Chia WK, Wang WW, Teo M, et al (2011) A phase II study evaluating the safety and efficacy of an adenovirus-{Delta}LMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma. Ann Oncol","DOI":"10.1093\/annonc\/mdr341"},{"key":"16_CR6","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1038\/cti.2014.27","volume":"4","author":"JI Cohen","year":"2015","unstructured":"Cohen JI (2015) Epstein\u2013barr virus vaccines. Clin Transl Immunol 4:e32","journal-title":"Clin Transl Immunol"},{"issue":"30","key":"16_CR7","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1016\/j.vaccine.2013.04.071","volume":"31","author":"X Cui","year":"2013","unstructured":"Cui X, Cao Z, Sen G et al (2013) A novel tetrameric gp350 1-470 as a potential Epstein-barr virus vaccine. Vaccine 31(30):3039\u20133045","journal-title":"Vaccine"},{"issue":"2","key":"16_CR8","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.semcancer.2012.01.004","volume":"22","author":"CW Dawson","year":"2012","unstructured":"Dawson CW, Port RJ, Young LS (2012) The role of the EBV-encoded latent membrane proteins LMP1 and LMP2 in the pathogenesis of nasopharyngeal carcinoma (NPC). Semin Cancer Biol 22(2):144\u2013153","journal-title":"Semin Cancer Biol"},{"issue":"6","key":"16_CR9","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/S1470-2045(12)70137-7","volume":"13","author":"C de Martel","year":"2012","unstructured":"de Martel C, Ferlay J, Franceschi S et al (2012) Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 13(6):607\u2013615","journal-title":"Lancet Oncol"},{"issue":"8","key":"16_CR10","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1182\/blood-2002-10-3092","volume":"101","author":"J Duraiswamy","year":"2003","unstructured":"Duraiswamy J, Sherritt M, Thomson S et al (2003) Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma. Blood 101(8):3150\u20133156","journal-title":"Blood"},{"issue":"4","key":"16_CR11","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1158\/0008-5472.CAN-03-2196","volume":"64","author":"J Duraiswamy","year":"2004","unstructured":"Duraiswamy J, Bharadwaj M, Tellam J et al (2004) Induction of therapeutic T-cell responses to subdominant tumor-associated viral oncogene after immunization with replication-incompetent polyepitope adenovirus vaccine. Cancer Res 64(4):1483\u20131489","journal-title":"Cancer Res"},{"issue":"3","key":"16_CR12","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1128\/JVI.01409-07","volume":"82","author":"SL Elliott","year":"2008","unstructured":"Elliott SL, Suhrbier A, Miles JJ et al (2008) Phase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosis. J Virol 82(3):1448\u20131457","journal-title":"J Virol"},{"issue":"2","key":"16_CR13","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1002\/jmv.1890270210","volume":"27","author":"EA Emini","year":"1989","unstructured":"Emini EA, Schleif WA, Silberklang M, Lehman D, Ellis RW (1989) Vero cell-expressed Epstein-barr virus (EBV) gp350\/220 protects marmosets from EBV challenge. J Med Virol 27(2):120\u2013123","journal-title":"J Med Virol"},{"issue":"7335","key":"16_CR14","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/S0140-6736(64)91524-7","volume":"1","author":"MA Epstein","year":"1964","unstructured":"Epstein MA, Achong BG, Barr YM (1964) Virus particles in cultured lymphoblasts from Burkitt\u2019s lymphoma. Lancet 1(7335):702\u2013703","journal-title":"Lancet"},{"issue":"6043","key":"16_CR15","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/318287a0","volume":"318","author":"MA Epstein","year":"1985","unstructured":"Epstein MA, Morgan AJ, Finerty S, Randle BJ, Kirkwood JK (1985) Protection of cottontop tamarins against Epstein-barr virus-induced malignant lymphoma by a prototype subunit vaccine. Nature 318(6043):287\u2013289","journal-title":"Nature"},{"issue":"5","key":"16_CR16","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/j.1440-1827.2010.02533.x","volume":"60","author":"M Fukayama","year":"2010","unstructured":"Fukayama M (2010) Epstein-Barr virus and gastric carcinoma. Pathol Int 60(5):337\u2013350","journal-title":"Pathol Int"},{"issue":"7","key":"16_CR17","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1182\/blood-2006-04-015164","volume":"108","author":"MK Gandhi","year":"2006","unstructured":"Gandhi MK, Lambley E, Duraiswamy J et al (2006) Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients. Blood 108(7):2280\u20132289","journal-title":"Blood"},{"issue":"4","key":"16_CR18","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1182\/blood-2007-01-066100","volume":"110","author":"MK Gandhi","year":"2007","unstructured":"Gandhi MK, Moll G, Smith C et al (2007) Galectin-1 mediated suppression of Epstein-barr virus specific T-cell immunity in classic Hodgkin lymphoma. Blood 110(4):1326\u20131329","journal-title":"Blood"},{"issue":"6","key":"16_CR19","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1002\/ijc.10653","volume":"101","author":"R Gavioli","year":"2002","unstructured":"Gavioli R, Vertuani S, Masucci MG (2002) Proteasome inhibitors reconstitute the presentation of cytotoxic T-cell epitopes in Epstein-barr virus-associated tumors. Int J Cancer 101(6):532\u2013538","journal-title":"Int J Cancer"},{"issue":"5","key":"16_CR20","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1182\/blood-2002-05-1514","volume":"101","author":"S Gottschalk","year":"2003","unstructured":"Gottschalk S, Edwards OL, Sili U et al (2003) Generating CTLs against the subdominant Epstein-barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood 101(5):1905\u20131912","journal-title":"Blood"},{"key":"16_CR21","first-page":"171","volume":"84","author":"SY Gu","year":"1995","unstructured":"Gu SY, Huang TM, Ruan L et al (1995) First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen. Dev Biol Stand 84:171\u2013177","journal-title":"Dev Biol Stand"},{"issue":"4","key":"16_CR22","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1182\/blood-2008-03-148072","volume":"112","author":"C Gurer","year":"2008","unstructured":"Gurer C, Strowig T, Brilot F et al (2008) Targeting the nuclear antigen 1 of Epstein-barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses. Blood 112(4):1231\u20131239","journal-title":"Blood"},{"issue":"1","key":"16_CR23","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1006\/viro.2001.1141","volume":"290","author":"KM Haan","year":"2001","unstructured":"Haan KM, Lee SK, Longnecker R (2001) Different functional domains in the cytoplasmic tail of glycoprotein B are involved in Epstein-barr virus-induced membrane fusion. Virology 290(1):106\u2013114","journal-title":"Virology"},{"key":"16_CR100","doi-asserted-by":"publisher","unstructured":"Hagn\u00a0M,\u00a0Panikkar\u00a0A, Smith C, Balfour HH Jr,\u00a0Khanna\u00a0R, Voskoboinik I, Trapani JA (2015) B cell-derived circulating granzyme B is afeature of acute infectious mononucleosis.\u00a0Clin Transl Immunology. 4(6):e38. doi:10.1038\/cti.2015.10","DOI":"10.1038\/cti.2015.10"},{"key":"16_CR24","doi-asserted-by":"crossref","unstructured":"Handel AE, Williamson AJ, Disanto G, Handunnetthi L, Giovannoni G, Ramagopalan SV (2010) An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis. PLoS ONE 5(9)","DOI":"10.1371\/journal.pone.0012496"},{"issue":"1","key":"16_CR25","doi-asserted-by":"publisher","first-page":"R3","DOI":"10.1186\/ar4429","volume":"16","author":"P Hanlon","year":"2014","unstructured":"Hanlon P, Avenell A, Aucott L, Vickers MA (2014) Systematic review and meta-analysis of the sero-epidemiological association between Epstein-Barr virus and systemic lupus erythematosus. Arthritis Res Ther 16(1):R3","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"16_CR26","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1084\/jem.20011692","volume":"195","author":"AD Hislop","year":"2002","unstructured":"Hislop AD, Annels NE, Gudgeon NH, Leese AM, Rickinson AB (2002) Epitope-specific evolution of human CD8(+) T cell responses from primary to persistent phases of Epstein-barr virus infection. J Exp Med 195(7):893\u2013905","journal-title":"J Exp Med"},{"issue":"14","key":"16_CR27","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1056\/NEJMoa023141","volume":"349","author":"H Hjalgrim","year":"2003","unstructured":"Hjalgrim H, Askling J, Rostgaard K et al (2003) Characteristics of Hodgkin\u2019s lymphoma after infectious mononucleosis. N Engl J Med 349(14):1324\u20131332","journal-title":"N Engl J Med"},{"issue":"5","key":"16_CR28","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.1073\/pnas.77.5.2979","volume":"77","author":"GJ Hoffman","year":"1980","unstructured":"Hoffman GJ, Lazarowitz SG, Hayward SD (1980) Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-barr virus identifies a membrane antigen and a neutralizing antigen. Proc Natl Acad Sci USA 77(5):2979\u20132983","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"16_CR29","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1158\/0008-5472.CAN-12-2448","volume":"73","author":"EP Hui","year":"2013","unstructured":"Hui EP, Taylor GS, Jia H et al (2013) Phase I trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients. Cancer Res 73(6):1676\u20131688","journal-title":"Cancer Res"},{"issue":"7\u20138","key":"16_CR30","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/S0264-410X(98)00248-5","volume":"17","author":"WT Jackman","year":"1999","unstructured":"Jackman WT, Mann KA, Hoffmann HJ, Spaete RR (1999) Expression of Epstein-Barr virus gp350 as a single chain glycoprotein for an EBV subunit vaccine. Vaccine 17(7\u20138):660\u2013668","journal-title":"Vaccine"},{"issue":"1","key":"16_CR31","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.virusres.2010.07.026","volume":"153","author":"K Kanai","year":"2010","unstructured":"Kanai K, Takashima K, Okuno K et al (2010) Lifelong persistent EBV infection of rabbits with EBER1-positive lymphocyte infiltration and mild sublethal hemophagocytosis. Virus Res 153(1):172\u2013178","journal-title":"Virus Res"},{"key":"16_CR101","doi-asserted-by":"publisher","unstructured":"Kanekiyo\u00a0M,\u00a0Bu W,\u00a0Joyce MG,\u00a0Meng G,\u00a0Whittle JR,\u00a0Baxa U,\u00a0Yamamoto T,\u00a0Narpala S,\u00a0Todd JP,\u00a0Rao SS,\u00a0McDermott AB,\u00a0Koup RA,\u00a0Rossmann MG, Mascola JR,\u00a0Graham BS,\u00a0Cohen\u00a0JI, Nabel GJ (2015)\u00a0Rational design of an epstein-barr virus vaccine targeting the receptor-binding site.\u00a0Cell\u00a012. doi:10.1016\/j.cell.2015.07.043. [Epub ahead of print]","DOI":"10.1016\/j.cell.2015.07.043"},{"key":"16_CR32","doi-asserted-by":"crossref","unstructured":"Khanna R, Moss DJ, Burrows SR (1999) Vaccine strategies against Epstein-barr virus-associated diseases: lessons from studies on cytotoxic T-cell-mediated immune regulation. Immunol Rev 170:49\u201364","DOI":"10.1111\/j.1600-065X.1999.tb01328.x"},{"issue":"18","key":"16_CR33","doi-asserted-by":"publisher","first-page":"10391","DOI":"10.1073\/pnas.96.18.10391","volume":"96","author":"R Khanna","year":"1999","unstructured":"Khanna R, Bell S, Sherritt M et al (1999b) Activation and adoptive transfer of Epstein-barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc Natl Acad Sci USA 96(18):10391\u201310396","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"16_CR34","doi-asserted-by":"publisher","first-page":"4721","DOI":"10.1128\/JVI.03744-13","volume":"88","author":"R Leskowitz","year":"2014","unstructured":"Leskowitz R, Fogg MH, Zhou XY et al (2014) Adenovirus-based vaccines against rhesus lymphocryptovirus EBNA-1 induce expansion of specific CD8+ and CD4+ T cells in persistently infected rhesus macaques. J Virol 88(9):4721\u20134735","journal-title":"J Virol"},{"issue":"9","key":"16_CR35","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1182\/blood-2012-08-450775","volume":"121","author":"CS Leung","year":"2013","unstructured":"Leung CS, Maurer MA, Meixlsperger S et al (2013) Robust T-cell stimulation by Epstein-barr virus-transformed B cells after antigen targeting to DEC-205. Blood 121(9):1584\u20131594","journal-title":"Blood"},{"issue":"3","key":"16_CR36","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/CJI.0b013e31828bd87b","volume":"36","author":"F Li","year":"2013","unstructured":"Li F, Song D, Lu Y, Zhu H, Chen Z, He X (2013) Delayed-type hypersensitivity (DTH) Immune Response related with EBV-DNA in nasopharyngeal carcinoma treated with autologous dendritic cell vaccination after radiotherapy. J Immunother 36(3):208\u2013214","journal-title":"J Immunother"},{"issue":"23","key":"16_CR37","first-page":"6952","volume":"62","author":"CL Lin","year":"2002","unstructured":"Lin CL, Lo WF, Lee TH et al (2002) Immunization with Epstein-Barr Virus (EBV) peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma. Cancer Res 62(23):6952\u20136958","journal-title":"Cancer Res"},{"issue":"21","key":"16_CR38","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1056\/NEJMcp1001116","volume":"362","author":"K Luzuriaga","year":"2010","unstructured":"Luzuriaga K, Sullivan JL (2010) Infectious mononucleosis. N Engl J Med 362(21):1993\u20132000","journal-title":"N Engl J Med"},{"issue":"25","key":"16_CR39","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.1182\/blood-2012-12-473413","volume":"121","author":"S Meixlsperger","year":"2013","unstructured":"Meixlsperger S, Leung CS, Ramer PC et al (2013) CD141+ dendritic cells produce prominent amounts of IFN-alpha after dsRNA recognition and can be targeted via DEC-205 in humanized mice. Blood 121(25):5034\u20135044","journal-title":"Blood"},{"issue":"5321","key":"16_CR40","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1126\/science.276.5321.2030","volume":"276","author":"A Moghaddam","year":"1997","unstructured":"Moghaddam A, Rosenzweig M, Lee-Parritz D, Annis B, Johnson RP, Wang F (1997) An animal model for acute and persistent Epstein-barr virus infection. Science 276(5321):2030\u20132033","journal-title":"Science"},{"issue":"6","key":"16_CR41","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1002\/ijc.2910220604","volume":"22","author":"DJ Moss","year":"1978","unstructured":"Moss DJ, Rickinson AB, Pope JH (1978) Long-term T-cell-mediated immunity to Epstein-barr virus in man. I. Complete regression of virus-induced transformation in cultures of seropositive donor leukocytes. Int J Cancer 22(6):662\u2013668","journal-title":"Int J Cancer"},{"issue":"24","key":"16_CR42","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1016\/j.vaccine.2007.04.008","volume":"25","author":"M Moutschen","year":"2007","unstructured":"Moutschen M, Leonard P, Sokal EM et al (2007) Phase I\/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-barr virus vaccine in healthy adults. Vaccine 25(24):4697\u20134705","journal-title":"Vaccine"},{"issue":"3","key":"16_CR43","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1053\/j.gastro.2009.05.001","volume":"137","author":"G Murphy","year":"2009","unstructured":"Murphy G, Pfeiffer R, Camargo MC, Rabkin CS (2009) Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location. Gastroenterology 137(3):824\u2013833","journal-title":"Gastroenterology"},{"key":"16_CR102","doi-asserted-by":"crossref","unstructured":"Panikkar\u00a0A, Smith C, Hislop A, Tellam N, Dasari V, Hogquist KA, Wykes M, Moss DJ, Rickinson A, Balfour HH Jr,\u00a0Khanna\u00a0R (2015a)\u00a0Impaired Epstein-Barr Virus-specific neutralizing antibody response during acute infectious mononucleosis is coincident with global B-Cell dysfunction.\u00a0J Virol 89(17):9137\u201341","DOI":"10.1128\/JVI.01293-15"},{"key":"16_CR103","doi-asserted-by":"crossref","unstructured":"Panikkar\u00a0A,\u00a0Smith C,\u00a0Hislop A,\u00a0Tellam N,\u00a0Dasari V,\u00a0Hogquist KA,\u00a0Wykes M,\u00a0Moss DJ,\u00a0Rickinson A,\u00a0Balfour HH Jr,\u00a0Khanna\u00a0R (2015b) Cytokine-mediated loss of blood dendritic cells during Epstein-Barr Virus-associated acute infectious mononucleosis: Implication for immune dysregulation.\u00a0J Infect Dis. jiv340 [Epub ahead of print]","DOI":"10.1093\/infdis\/jiv340"},{"issue":"8","key":"16_CR44","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/j.vaccine.2006.10.047","volume":"25","author":"J Parrino","year":"2007","unstructured":"Parrino J, McCurdy LH, Larkin BD et al (2007) Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naive and vaccinia-immune individuals. Vaccine 25(8):1513\u20131525","journal-title":"Vaccine"},{"issue":"4","key":"16_CR45","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1128\/JVI.02533-12","volume":"87","author":"S Pavlova","year":"2013","unstructured":"Pavlova S, Feederle R, Gartner K, Fuchs W, Granzow H, Delecluse HJ (2013) An Epstein-barr virus mutant produces immunogenic defective particles devoid of viral DNA. J Virol 87(4):2011\u20132022","journal-title":"J Virol"},{"issue":"5","key":"16_CR46","first-page":"989","volume":"45","author":"G Pearson","year":"1970","unstructured":"Pearson G, Dewey F, Klein G, Henle G, Henle W (1970) Relation between neutralization of Epstein-barr virus and antibodies to cell-membrane antigens-induced by the virus. J Natl Cancer Inst 45(5):989\u2013995","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"16_CR47","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1097\/TP.0b013e3181b9d918","volume":"88","author":"L Rees","year":"2009","unstructured":"Rees L, Tizard EJ, Morgan AJ et al (2009) A phase I trial of epstein-barr virus gp350 vaccine for children with chronic kidney disease awaiting transplantation. Transplantation 88(8):1025\u20131029","journal-title":"Transplantation"},{"issue":"5","key":"16_CR48","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1002\/ijc.2910230505","volume":"23","author":"AB Rickinson","year":"1979","unstructured":"Rickinson AB, Moss DJ, Pope JH (1979) Long-term C-cell-mediated immunity to Epstein-barr virus in man. II. Components necessary for regression in virus-infected leukocyte cultures. Int J Cancer 23(5):610\u2013617","journal-title":"Int J Cancer"},{"issue":"4","key":"16_CR49","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.it.2014.01.003","volume":"35","author":"AB Rickinson","year":"2014","unstructured":"Rickinson AB, Long HM, Palendira U, Munz C, Hislop AD (2014) Cellular immune controls over Epstein-barr virus infection: new lessons from the clinic and the laboratory. Trends Immunol 35(4):159\u2013169","journal-title":"Trends Immunol"},{"issue":"1","key":"16_CR50","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1128\/JVI.76.1.421-426.2002","volume":"76","author":"P Rivailler","year":"2002","unstructured":"Rivailler P, Jiang H, Cho YG, Quink C, Wang F (2002) Complete nucleotide sequence of the rhesus lymphocryptovirus: genetic validation for an Epstein-barr virus animal model. J Virol 76(1):421\u2013426","journal-title":"J Virol"},{"issue":"8941","key":"16_CR51","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0140-6736(95)91150-2","volume":"345","author":"CM Rooney","year":"1995","unstructured":"Rooney CM, Smith CA, Ng CY et al (1995) Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 345(8941):9\u201313","journal-title":"Lancet"},{"issue":"24","key":"16_CR52","doi-asserted-by":"publisher","first-page":"13105","DOI":"10.1128\/JVI.05598-11","volume":"85","author":"R Ruiss","year":"2011","unstructured":"Ruiss R, Jochum S, Wanner G, Reisbach G, Hammerschmidt W, Zeidler R (2011) A virus-like particle-based Epstein-barr virus vaccine. J Virol 85(24):13105\u201313113","journal-title":"J Virol"},{"issue":"10","key":"16_CR53","doi-asserted-by":"publisher","first-page":"e1002308","DOI":"10.1371\/journal.ppat.1002308","volume":"7","author":"J Sashihara","year":"2011","unstructured":"Sashihara J, Hoshino Y, Bowman JJ et al (2011) Soluble rhesus lymphocryptovirus gp350 protects against infection and reduces viral loads in animals that become infected with virus after challenge. PLoS Pathog 7(10):e1002308","journal-title":"PLoS Pathog"},{"issue":"21","key":"16_CR54","doi-asserted-by":"publisher","first-page":"5663","DOI":"10.1182\/blood-2010-09-305979","volume":"117","author":"K Sato","year":"2011","unstructured":"Sato K, Misawa N, Nie C et al (2011) A novel animal model of Epstein-barr virus-associated hemophagocytic lymphohistiocytosis in humanized mice. Blood 117(21):5663\u20135673","journal-title":"Blood"},{"issue":"3","key":"16_CR55","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.trim.2006.10.006","volume":"17","author":"K Sebelin-Wulf","year":"2007","unstructured":"Sebelin-Wulf K, Nguyen TD, Oertel S et al (2007) Quantitative analysis of EBV-specific CD4\/CD8 T cell numbers, absolute CD4\/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD. Transpl Immunol 17(3):203\u2013210","journal-title":"Transpl Immunol"},{"issue":"9","key":"16_CR56","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1097\/01.TP.0000058745.02123.6F","volume":"75","author":"MA Sherritt","year":"2003","unstructured":"Sherritt MA, Bharadwaj M, Burrows JM et al (2003) Reconstitution of the latent T-lymphocyte response to Epstein-barr virus is coincident with long-term recovery from posttransplant lymphoma after adoptive immunotherapy. Transplantation 75(9):1556\u20131560","journal-title":"Transplantation"},{"issue":"24","key":"16_CR57","doi-asserted-by":"publisher","first-page":"13904","DOI":"10.1128\/JVI.01947-13","volume":"87","author":"EL Silveira","year":"2013","unstructured":"Silveira EL, Fogg MH, Leskowitz RM et al (2013) Therapeutic vaccination against the rhesus lymphocryptovirus EBNA-1 homologue, rhEBNA-1, elicits T cell responses to novel epitopes in rhesus macaques. J Virol 87(24):13904\u201313910","journal-title":"J Virol"},{"issue":"10","key":"16_CR58","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1097\/00007890-200205270-00014","volume":"73","author":"F Smets","year":"2002","unstructured":"Smets F, Latinne D, Bazin H et al (2002) Ratio between Epstein-barr viral load and anti-Epstein-barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. Transplantation 73(10):1603\u20131610","journal-title":"Transplantation"},{"issue":"7","key":"16_CR59","doi-asserted-by":"publisher","first-page":"4897","DOI":"10.4049\/jimmunol.177.7.4897","volume":"177","author":"C Smith","year":"2006","unstructured":"Smith C, Cooper L, Burgess M et al (2006) Functional reversion of antigen-specific CD8+ T cells from patients with Hodgkin lymphoma following in vitro stimulation with recombinant polyepitope. J Immunol 177(7):4897\u20134906","journal-title":"J Immunol"},{"issue":"7","key":"16_CR60","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1002\/eji.200737933","volume":"38","author":"C Smith","year":"2008","unstructured":"Smith C, Martinez M, Cooper L, Rist M, Zhong J, Khanna R (2008) Generating functional CD8+ T cell memory response under transient CD4+ T cell deficiency: implications for vaccination of immunocompromised individuals. Eur J Immunol 38(7):1857\u20131866","journal-title":"Eur J Immunol"},{"issue":"12","key":"16_CR61","doi-asserted-by":"publisher","first-page":"6192","DOI":"10.1128\/JVI.00239-09","volume":"83","author":"C Smith","year":"2009","unstructured":"Smith C, Beagley L, Khanna R (2009a) Acquisition of polyfunctionality by Epstein-Barr virus-specific CD8+ T cells correlates with increased resistance to galectin-1-mediated suppression. J Virol 83(12):6192\u20136198","journal-title":"J Virol"},{"issue":"24","key":"16_CR62","doi-asserted-by":"publisher","first-page":"6148","DOI":"10.1182\/blood-2009-02-203687","volume":"113","author":"C Smith","year":"2009","unstructured":"Smith C, Wakisaka N, Crough T et al (2009b) Discerning regulation of cis- and trans-presentation of CD8+ T-cell epitopes by EBV-encoded oncogene LMP-1 through self-aggregation. Blood 113(24):6148\u20136152","journal-title":"Blood"},{"issue":"5","key":"16_CR63","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1158\/0008-5472.CAN-11-3399","volume":"72","author":"C Smith","year":"2012","unstructured":"Smith C, Tsang J, Beagley L et al (2012) Effective treatment of metastatic forms of Epstein-barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy. Cancer Res 72(5):1116\u20131125","journal-title":"Cancer Res"},{"issue":"12","key":"16_CR64","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1086\/523813","volume":"196","author":"EM Sokal","year":"2007","unstructured":"Sokal EM, Hoppenbrouwers K, Vandermeulen C et al (2007) Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-barr virus vaccine in healthy young adults. J Infect Dis 196(12):1749\u20131753","journal-title":"J Infect Dis"},{"issue":"6","key":"16_CR65","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1084\/jem.20081720","volume":"206","author":"T Strowig","year":"2009","unstructured":"Strowig T, Gurer C, Ploss A et al (2009) Priming of protective T cell responses against virus-induced tumors in mice with human immune system components. J Exp Med 206(6):1423\u20131434","journal-title":"J Exp Med"},{"issue":"3","key":"16_CR66","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jmv.21102","volume":"80","author":"K Takashima","year":"2008","unstructured":"Takashima K, Ohashi M, Kitamura Y et al (2008) A new animal model for primary and persistent Epstein-barr virus infection: human EBV-infected rabbit characteristics determined using sequential imaging and pathological analysis. J Med Virol 80(3):455\u2013466","journal-title":"J Med Virol"},{"issue":"2","key":"16_CR67","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1128\/JVI.78.2.768-778.2004","volume":"78","author":"GS Taylor","year":"2004","unstructured":"Taylor GS, Haigh TA, Gudgeon NH et al (2004) Dual stimulation of Epstein-barr virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma. J Virol 78(2):768\u2013778","journal-title":"J Virol"},{"key":"16_CR104","doi-asserted-by":"crossref","unstructured":"Taylor\u00a0GS, Jia H, Harrington K, Lee LW, Turner J, Ladell K, Price DA, Tanday M, Matthews J, Roberts C, Edwards C, McGuigan L, Hartley A, Wilson S, Hui EP, Chan AT,\u00a0Rickinson\u00a0AB, Steven NM (2014)\u00a0A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer.\u00a0Clin Cancer Res 20(19):5009\u201322","DOI":"10.1158\/1078-0432.CCR-14-1122-T"},{"issue":"10","key":"16_CR68","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1084\/jem.20040191","volume":"199","author":"J Tellam","year":"2004","unstructured":"Tellam J, Connolly G, Green KJ et al (2004) Endogenous presentation of CD8+ T cell epitopes from Epstein-barr virus-encoded nuclear antigen 1. J Exp Med 199(10):1421\u20131431","journal-title":"J Exp Med"},{"issue":"27","key":"16_CR69","doi-asserted-by":"publisher","first-page":"9319","DOI":"10.1073\/pnas.0801968105","volume":"105","author":"J Tellam","year":"2008","unstructured":"Tellam J, Smith C, Rist M et al (2008) Regulation of protein translation through mRNA structure influences MHC class I loading and T cell recognition. Proc Natl Acad Sci USA 105(27):9319\u20139324","journal-title":"Proc Natl Acad Sci USA"},{"issue":"13","key":"16_CR70","doi-asserted-by":"publisher","first-page":"5845","DOI":"10.1073\/pnas.92.13.5845","volume":"92","author":"SA Thomson","year":"1995","unstructured":"Thomson SA, Khanna R, Gardner J et al (1995) Minimal epitopes expressed in a recombinant polyepitope protein are processed and presented to CD8+ cytotoxic T cells: implications for vaccine design. Proc Natl Acad Sci USA 92(13):5845\u20135849","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"16_CR71","doi-asserted-by":"crossref","first-page":"822","DOI":"10.4049\/jimmunol.157.2.822","volume":"157","author":"SA Thomson","year":"1996","unstructured":"Thomson SA, Elliott SL, Sherritt MA et al (1996) Recombinant polyepitope vaccines for the delivery of multiple CD8 cytotoxic T cell epitopes. J Immunol 157(2):822\u2013826","journal-title":"J Immunol"},{"issue":"4","key":"16_CR72","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.4049\/jimmunol.160.4.1717","volume":"160","author":"SA Thomson","year":"1998","unstructured":"Thomson SA, Sherritt MA, Medveczky J et al (1998) Delivery of multiple CD8 cytotoxic T cell epitopes by DNA vaccination. J Immunol 160(4):1717\u20131723","journal-title":"J Immunol"},{"issue":"5667","key":"16_CR73","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1126\/science.1093933","volume":"304","author":"E Traggiai","year":"2004","unstructured":"Traggiai E, Chicha L, Mazzucchelli L et al (2004) Development of a human adaptive immune system in cord blood cell-transplanted mice. Science 304(5667):104\u2013107","journal-title":"Science"},{"issue":"2","key":"16_CR74","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.semcancer.2012.02.004","volume":"22","author":"SW Tsao","year":"2012","unstructured":"Tsao SW, Tsang CM, Pang PS, Zhang G, Chen H, Lo KW (2012) The biology of EBV infection in human epithelial cells. Semin Cancer Biol 22(2):137\u2013143","journal-title":"Semin Cancer Biol"},{"issue":"3","key":"16_CR75","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nm830","volume":"9","author":"SM Tugizov","year":"2003","unstructured":"Tugizov SM, Berline JW, Palefsky JM (2003) Epstein-barr virus infection of polarized tongue and nasopharyngeal epithelial cells. Nat Med 9(3):307\u2013314","journal-title":"Nat Med"},{"issue":"7","key":"16_CR76","doi-asserted-by":"crossref","first-page":"5552","DOI":"10.1128\/JVI.72.7.5552-5558.1998","volume":"72","author":"X Wang","year":"1998","unstructured":"Wang X, Kenyon WJ, Li Q, Mullberg J, Hutt-Fletcher LM (1998) Epstein-barr virus uses different complexes of glycoproteins gH and gL to infect B lymphocytes and epithelial cells. J Virol 72(7):5552\u20135558","journal-title":"J Virol"},{"issue":"6","key":"16_CR77","doi-asserted-by":"publisher","first-page":"e99857","DOI":"10.1371\/journal.pone.0099857","volume":"9","author":"G Xiong","year":"2014","unstructured":"Xiong G, Zhang B, Huang MY et al (2014) Epstein-Barr virus (EBV) infection in Chinese children: a retrospective study of age-specific prevalence. PLoS ONE 9(6):e99857","journal-title":"PLoS ONE"},{"issue":"5","key":"16_CR78","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1086\/590502","volume":"198","author":"M Yajima","year":"2008","unstructured":"Yajima M, Imadome K, Nakagawa A et al (2008) A new humanized mouse model of Epstein-barr virus infection that reproduces persistent infection, lymphoproliferative disorder, and cell-mediated and humoral immune responses. J Infect Dis 198(5):673\u2013682","journal-title":"J Infect Dis"}],"container-title":["Current Topics in Microbiology and Immunology","Epstein Barr Virus Volume 2"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-319-22834-1_16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T17:32:44Z","timestamp":1675877564000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-319-22834-1_16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"ISBN":["9783319228334","9783319228341"],"references-count":83,"URL":"https:\/\/doi.org\/10.1007\/978-3-319-22834-1_16","relation":{},"ISSN":["0070-217X","2196-9965"],"issn-type":[{"value":"0070-217X","type":"print"},{"value":"2196-9965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]},"assertion":[{"value":"2 October 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}